drugset

Drugs / Vutiglabridin

Follow last change Jul 2026 re-read 3 minutes ago

Vutiglabridin

Developed for: osteoarthritis, knee · Parkinson disease
Investigated by: Glaceum · Hallym University Medical Center · Inje University · Korea University Guro Hospital · Kyunghee University Medical Center · Samsung Medical Center
+5 more
· Seoul National University Bundang Hospital · Seoul National University Hospital · Severance Hospital · The Catholic University of Korea · Uijeongbu St. Mary Hospital

Trials 2

today NCT06845553 · Ph 2 NCT06329141 · Ph 2

20252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT06845553	Aug 2025 → Jul 2026 overdue	osteoarthritis, knee	Glaceum	Recruiting	No outcome recorded
Phase 2	NCT06329141	Jul 2024 → Dec 2025	Parkinson disease	Glaceum	Completed	No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	Vutiglabridin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06329141 ↗ 1 NCT06845553 ↗
Modality	Small molecule	— CHEMBL6068529 ↗
Route	Oral	“Once-daily oral administration” NCT06329141 ↗